While primarily used for its LDL-reducing capacities, PCSK9 inhibitors, much like SGLT2is, exhibit pleiotropic effects, including the attenuation of inflammation, reactive oxygen species (ROS), and endothelial dysfunction. The gene discussed is PCSK9; the disease is endothelial dysfunction.